Abstract
Background Erectile dysfunction is a common medical problem affecting many men. Although several intracavernosal therapies are available, their efficacy and safety have not been studied systematically. Methods We investigated the efficacy and safety of alprostadil formulated for intracavernosal treatment in three separate multi-institutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psychogenic, and mixed causes. Clinical and laboratory evaluations of erection and the feasibility and satisfactoriness of sexual activity as assessed both by the men and by their partners were the primary measures of efficacy. Results In a dose–response study of 296 men, all doses of alprostadil were superior to placebo and there was a significant dose–response relation (P<0.001), resulting in higher response rates with increasing doses of alprostadil (from 2.5 to 20 μg). In a dose-finding study of 201 men, the minimal effective dose was <2 μg in 23, 20, 38, and 23 percent of men with ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.